SCHEMBL257513

SCHEMBL257513

Cc1ccc(C(=O)c2ccc(OC(F)(F)F)cc2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP2 P12104 1/20 0.46
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
SLC22A12 Q96S37 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
TRPV1 Q8NER1 4/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
ABL1 P00519 1/20 0.43
VNN1 O95497 1/20 0.43
CHRNA1 P02708 1/20 0.43
CHRNG P07510 1/20 0.43
CHRNB1 P11230 1/20 0.43
CHRNB2 P17787 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25962679 0.88 TRPV1 (0.47) FABP2PPARGPPARASLC22A12NPC1
SCHEMBL257272 0.81 HPGD (0.64) NPC1RAB9AMEN1LMNAKMT2A
SCHEMBL2924706 0.80 HPGD (0.54) NPC1RAB9AMEN1LMNAKMT2A
SCHEMBL4475347 0.80 NPC1 (0.60) FABP2PPARGPPARASLC22A12NPC1
SCHEMBL15100883 0.80 SRD5A2 (0.54) NPC1RAB9ASMN1; SMN2CHRNA1CHRNG
SCHEMBL23388234 0.79 TRPV1 (0.47) FABP2PPARGPPARASLC22A12NPC1
SCHEMBL3833768 0.79 PPARA (0.63) FABP2PPARGPPARASLC22A12NPC1
SCHEMBL9912450 0.79 GPR3 (0.45) LMNASMN1; SMN2AKR1C2AKR1C1SLC6A4
Hydrochloric Acid SCHEMBL3539826 0.79 NPC1 (0.58) FABP2PPARGPPARASLC22A12NPC1
SCHEMBL257368 0.78 SMN1; SMN2 (0.56) NPC1RAB9AMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 FABP2 4513/4885PPARG 2629/4885PPARA 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.